Loading...
Studies demonstrate lower efficacy of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV) genotype 3–infected patients when cirrhosis is present. In the current industry-funded, phase III trial, investigators assessed whether adding ribavirin improves efficacy in these patients. Approximately 200 patients with HCV genotype 3 infection and compensated cirrhosis were randomized to receive a daily open-label regimen of sofosbuvir and velpatasvir (SOF/VEL) with or without ribavirin for 12 weeks.
The primary endpoint of sustained virologic response at 12 weeks after treatment ended (SVR12) was 91% without ribavirin and 96% with ribavirin. In a post-hoc analysis with stratification by prior treatment, SVR12 was not statistically super…